Immunome Inc. (IMNM) shares soared 6.04% in after-hours trading on Tuesday, following news of a significant insider purchase by the company's Chief Technology Officer (CTO).
According to a regulatory filing, Immunome's CTO Philip Tsai acquired 12,300 shares of common stock on March 24th. The total transaction amounted to approximately $103,600, signaling a strong vote of confidence in the company's future prospects from a key executive.
Insider buying, particularly by high-ranking officers such as the CTO, is often viewed positively by investors. It suggests that those with intimate knowledge of the company's operations and potential believe the stock is undervalued or has significant growth potential. This purchase by Tsai may have triggered increased investor interest, leading to the after-hours stock price surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.